BioSpace News Archive

Rizatriptan is utilized to treat migraine headaches with or without aura. Rizatriptan belongs to a class of medicines known as 5HT1-receptor agonists.

Biocom California today announced the inaugural Diversity, Equity and Inclusion Leadership Summit, a virtual event to further ignite action around DE&I in California’s life sciences industry, will be held on Thursday, August 26 from 9:00 am-1:00 pm PT.

W. L. Gore & Associates (Gore), today announced that five-year results of the U.S. prospective, multicenter study (N = 63) of endovascular repair of iliac aneurysms using the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE) were presented at the 2021 Society for Vascular Surgery Annual Meeting.

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its second quarter 2021 financial results after market close on Thursday, August 26, 2021.

Vaxart, Inc. (NASDAQ: VXRT), today announced the creation of an eight-member Scientific and Clinical Advisory Board.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment of Mitchell E. Levinson to the newly created role of Chief Strategy Officer, effective immediately, in addition to the continuation of his role as a member of the Pulse Biosciences Board of Directors.

As part of its growing global mission, the Urology Care Foundation is proud to announce Una Jeanie Lee , MD and David E. Rapp , MD have been selected as 2021 Urology Care Foundation Humanitarian Grant recipients and will each receive $4,500 in funding.

Pressure BioSciences, Inc. today reported continued strong financial results for the second quarter ended June 30, 2021, provided a business update, and offered guidance for the remainder of FY 2021.

A breakthrough offering of 12 anterior, posterior, and lateral plates designed to work with the Phantom® TTC Fusion Nail in cases where maximum strength is required.

Multinational clinical trial is the first successful clinical trial for GM2 Gangliosidosis